L-Histidine for Anemia

Research suggests that L-histidine may play a supporting role in anemia management, particularly in the context of chronic kidney disease (CKD), where histidine deficiency is commonly observed and where the amino acid is thought to contribute to red blood cell production, iron absorption, and protection against iron-induced oxidative stress. A 2018 review article argues that histidine supplementation warrants consideration as a strategy to reduce reactive oxygen species generated by iron therapy in CKD-related anemia, citing its free radical-scavenging and metal ion-binding properties. A 1990 experimental animal study examined L-carnosine — a dipeptide that contains L-histidine — and found some protective effects on blood cells in models of chemotherapy-induced and hemolytic anemia, though notably the membrane-stabilizing mechanism observed required the intact carnosine molecule rather than L-histidine alone, making it difficult to attribute those effects directly to histidine. The overall evidence base is narrow, consisting primarily of a single review and animal or mechanistic studies rather than controlled human clinical trials, and the majority of studies provided with this entry are unrelated to anemia or histidine, so firm conclusions about the direct therapeutic role of L-histidine in anemia cannot be drawn from the available literature.